Skip to content

Evaluation of the effects of lemongrass on clinical and electrodiagnostic symptoms of type 2 diabetes

Evaluation of therapeutic effects of lemongrass capsule on clinical and electrodiagnostic symptoms of patients with type 2 diabetes: a double-blind clinical trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200612047739N1
Enrollment
60
Registered
2021-01-02
Start date
2020-12-20
Completion date
Unknown
Last updated
2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes. Type 1 diabetes mellitus

Interventions

Intervention 1: Intervention group: In this group, one gr of lemongrass will be used in the form of 500 mg oral capsules, made in Isfahan University of Medical Sciences, in two divided doses for three

Sponsors

Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Type 2 diabetes Age over 18 years Body mass index 18.5–30 kg / m Willing to participate in the study

Exclusion criteria

Exclusion criteria: Type 1 diabetes Pregnancy or other specific types of diabetes Insulin therapy over the past three months Having serious gastrointestinal (GI) diseases including stomach ulcers and gastrointestinal bleeding Having an autoimmune disease Osteoarthritis Chronic uremia Use of drugs that affect the symptoms of neuropathy such as antidepressants and anticonvulsants Allergy to Lemongrass

Design outcomes

Primary

MeasureTime frame
Clinical signs of neuropathy. Timepoint: Beginning and end of three months of treatment. Method of measurement: Physical examination.;Electrodiagnostic findings. Timepoint: Beginning and end of three months of treatment. Method of measurement: An electromyographic device will be used for this purpose.;Laboratory findings including Fasting blood sugar and hemoglobin A1c. Timepoint: Beginning and end of three months of treatment. Method of measurement: Based on laboratory evaluation of patients.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMorteza Rajabi

Tabriz University of Medical Sciences

rajabi.m@tbzmed.ac.ir+98 41 3337 6923

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026